Clinical Trials Logo

Epithelial Ovarian Cancer clinical trials

View clinical trials related to Epithelial Ovarian Cancer.

Filter by:

NCT ID: NCT05385068 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

t
Start date: June 2022
Phase: Phase 2
Study type: Interventional

This study will be an open-label, single-arm, prospective, exploratory phase II trial to investigate the efficacy and safety of niraparib maintenance retreatment in platinum- sensitive recurrent (PSR) epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer).

NCT ID: NCT05236686 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Start date: February 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.

NCT ID: NCT05187208 Not yet recruiting - Ovarian Cancer Clinical Trials

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

POLO
Start date: January 2022
Phase: Phase 4
Study type: Interventional

This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.

NCT ID: NCT04986371 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

RENI-1
Start date: August 10, 2021
Phase:
Study type: Observational

This is an open-label, single-arm, multi-center、non-interventional real-world study, which evaluate treatment pattern, safety and efficacy of Niraparib as first-line maintenance treatment for Chinese patient with newly diagnosed ovarian cancer , fallopian tube cancer, and primary peritoneal cancer in real world clinical practice.

NCT ID: NCT04983550 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Start date: September 2021
Phase: Phase 2
Study type: Interventional

This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome injection in patients with platinum-resistant relapsed epithelial ovarian cancer.

NCT ID: NCT04889495 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Start date: September 1, 2024
Phase:
Study type: Observational

This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.

NCT ID: NCT04846842 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer. The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.

NCT ID: NCT04515602 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Start date: January 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to answer the fundamental question 'The Optimal Timing of Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform translational study.

NCT ID: NCT04421547 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

Efficacy of Letrozole in Recurrent Ovarian Cancer

MITO32
Start date: June 1, 2020
Phase: Phase 3
Study type: Interventional

Randomized phase III multicenter study investigating the role of letrozole in heavily pretreated recurrent ovarian cancer.

NCT ID: NCT03692637 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single centre、single arm、open-label,to investigate the safety and efficacy of anti-Mesothelin Car NK Cells With Epithelial ovarian cancer